A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Trial Profile

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms DETERMINE
  • Sponsors MedImmune
  • Most Recent Events

    • 15 Aug 2017 Planned End Date changed from 1 Apr 2017 to 2 Apr 2018.
    • 17 Jul 2017 Results published in the Lancet Oncology
    • 05 Apr 2017 Results (n=376) assessing relationship of exposure with OS, and the impact of potential confounders, presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top